| . | Treatment duration (d) . | |||
|---|---|---|---|---|
| Adalimumab . | Infliximab . | Vedolizumab . | Ustekinumab . | |
| Crohn’s disease | ||||
| First line | 1605 | 956 | 329 | 118 |
| Mean (SD) | 435.2 (457.1) | 411.6 (408.9) | 413.1 (375.8) | 206.6 (293.0) |
| Median | 266.0 | 272.0 | 269.0 | 106.5 |
| Second line | 553 | 720 | 886 | 849 |
| Mean (SD) | 454.2 (455.1) | 459.7 (447.3) | 458.1 (425.3) | 353.6 (327.3) |
| Median | 318.0 | 313.5 | 318.0 | 235.0 |
| Ulcerative colitis | ||||
| First line | 764 | 661 | 213 | NA |
| Mean (SD) | 279.0 (328.7) | 325.1 (352.8) | 258.3 (293.8) | NA |
| Median | 167.0 | 213.0 | 161.0 | NA |
| Second line | 330 | 450 | 776 | 84 |
| Mean (SD) | 419.6 (474.1) | 423.6 (445.8) | 459.5 (448.7) | 240.1 (311.7) |
| Median | 237.5 | 239.5 | 288.0 | 98.5 |
| . | Treatment duration (d) . | |||
|---|---|---|---|---|
| Adalimumab . | Infliximab . | Vedolizumab . | Ustekinumab . | |
| Crohn’s disease | ||||
| First line | 1605 | 956 | 329 | 118 |
| Mean (SD) | 435.2 (457.1) | 411.6 (408.9) | 413.1 (375.8) | 206.6 (293.0) |
| Median | 266.0 | 272.0 | 269.0 | 106.5 |
| Second line | 553 | 720 | 886 | 849 |
| Mean (SD) | 454.2 (455.1) | 459.7 (447.3) | 458.1 (425.3) | 353.6 (327.3) |
| Median | 318.0 | 313.5 | 318.0 | 235.0 |
| Ulcerative colitis | ||||
| First line | 764 | 661 | 213 | NA |
| Mean (SD) | 279.0 (328.7) | 325.1 (352.8) | 258.3 (293.8) | NA |
| Median | 167.0 | 213.0 | 161.0 | NA |
| Second line | 330 | 450 | 776 | 84 |
| Mean (SD) | 419.6 (474.1) | 423.6 (445.8) | 459.5 (448.7) | 240.1 (311.7) |
| Median | 237.5 | 239.5 | 288.0 | 98.5 |
Values are n, unless otherwise indicated.
Abbreviations: NA, not applicable.
| . | Treatment duration (d) . | |||
|---|---|---|---|---|
| Adalimumab . | Infliximab . | Vedolizumab . | Ustekinumab . | |
| Crohn’s disease | ||||
| First line | 1605 | 956 | 329 | 118 |
| Mean (SD) | 435.2 (457.1) | 411.6 (408.9) | 413.1 (375.8) | 206.6 (293.0) |
| Median | 266.0 | 272.0 | 269.0 | 106.5 |
| Second line | 553 | 720 | 886 | 849 |
| Mean (SD) | 454.2 (455.1) | 459.7 (447.3) | 458.1 (425.3) | 353.6 (327.3) |
| Median | 318.0 | 313.5 | 318.0 | 235.0 |
| Ulcerative colitis | ||||
| First line | 764 | 661 | 213 | NA |
| Mean (SD) | 279.0 (328.7) | 325.1 (352.8) | 258.3 (293.8) | NA |
| Median | 167.0 | 213.0 | 161.0 | NA |
| Second line | 330 | 450 | 776 | 84 |
| Mean (SD) | 419.6 (474.1) | 423.6 (445.8) | 459.5 (448.7) | 240.1 (311.7) |
| Median | 237.5 | 239.5 | 288.0 | 98.5 |
| . | Treatment duration (d) . | |||
|---|---|---|---|---|
| Adalimumab . | Infliximab . | Vedolizumab . | Ustekinumab . | |
| Crohn’s disease | ||||
| First line | 1605 | 956 | 329 | 118 |
| Mean (SD) | 435.2 (457.1) | 411.6 (408.9) | 413.1 (375.8) | 206.6 (293.0) |
| Median | 266.0 | 272.0 | 269.0 | 106.5 |
| Second line | 553 | 720 | 886 | 849 |
| Mean (SD) | 454.2 (455.1) | 459.7 (447.3) | 458.1 (425.3) | 353.6 (327.3) |
| Median | 318.0 | 313.5 | 318.0 | 235.0 |
| Ulcerative colitis | ||||
| First line | 764 | 661 | 213 | NA |
| Mean (SD) | 279.0 (328.7) | 325.1 (352.8) | 258.3 (293.8) | NA |
| Median | 167.0 | 213.0 | 161.0 | NA |
| Second line | 330 | 450 | 776 | 84 |
| Mean (SD) | 419.6 (474.1) | 423.6 (445.8) | 459.5 (448.7) | 240.1 (311.7) |
| Median | 237.5 | 239.5 | 288.0 | 98.5 |
Values are n, unless otherwise indicated.
Abbreviations: NA, not applicable.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
